                         SEQUENCE LISTING

<110>  THE BROAD INSTITUTE, INC.
 
<120>  NEURONAL ASSAY METHOD INVOLVING CALCINEURIN

<130>  01180-0002-00PCT

<150>  US 62/546,464
<151>  2017-08-16

<160>  18    

<170>  PatentIn version 3.5

<210>  1
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Phosphospecific S469 CNA-alpha antibody epitope


<220>
<221>  MOD_RES
<222>  (7)..(7)
<223>  Phosphorylated serine

<400>  1

Pro Gln His Lys Ile Thr Ser Phe Glu Glu Ala 
1               5                   10      


<210>  2
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Pan CNA-alpha antibody epitope

<400>  2

Arg Arg Asp Ala Met Pro Ser Asp Ala Asn Leu Asn Ser Ile Asn Lys 
1               5                   10                  15      


<210>  3
<211>  521
<212>  PRT
<213>  Homo sapiens

<400>  3

Met Ser Glu Pro Lys Ala Ile Asp Pro Lys Leu Ser Thr Thr Asp Arg 
1               5                   10                  15      


Val Val Lys Ala Val Pro Phe Pro Pro Ser His Arg Leu Thr Ala Lys 
            20                  25                  30          


Glu Val Phe Asp Asn Asp Gly Lys Pro Arg Val Asp Ile Leu Lys Ala 
        35                  40                  45              


His Leu Met Lys Glu Gly Arg Leu Glu Glu Ser Val Ala Leu Arg Ile 
    50                  55                  60                  


Ile Thr Glu Gly Ala Ser Ile Leu Arg Gln Glu Lys Asn Leu Leu Asp 
65                  70                  75                  80  


Ile Asp Ala Pro Val Thr Val Cys Gly Asp Ile His Gly Gln Phe Phe 
                85                  90                  95      


Asp Leu Met Lys Leu Phe Glu Val Gly Gly Ser Pro Ala Asn Thr Arg 
            100                 105                 110         


Tyr Leu Phe Leu Gly Asp Tyr Val Asp Arg Gly Tyr Phe Ser Ile Glu 
        115                 120                 125             


Cys Val Leu Tyr Leu Trp Ala Leu Lys Ile Leu Tyr Pro Lys Thr Leu 
    130                 135                 140                 


Phe Leu Leu Arg Gly Asn His Glu Cys Arg His Leu Thr Glu Tyr Phe 
145                 150                 155                 160 


Thr Phe Lys Gln Glu Cys Lys Ile Lys Tyr Ser Glu Arg Val Tyr Asp 
                165                 170                 175     


Ala Cys Met Asp Ala Phe Asp Cys Leu Pro Leu Ala Ala Leu Met Asn 
            180                 185                 190         


Gln Gln Phe Leu Cys Val His Gly Gly Leu Ser Pro Glu Ile Asn Thr 
        195                 200                 205             


Leu Asp Asp Ile Arg Lys Leu Asp Arg Phe Lys Glu Pro Pro Ala Tyr 
    210                 215                 220                 


Gly Pro Met Cys Asp Ile Leu Trp Ser Asp Pro Leu Glu Asp Phe Gly 
225                 230                 235                 240 


Asn Glu Lys Thr Gln Glu His Phe Thr His Asn Thr Val Arg Gly Cys 
                245                 250                 255     


Ser Tyr Phe Tyr Ser Tyr Pro Ala Val Cys Glu Phe Leu Gln His Asn 
            260                 265                 270         


Asn Leu Leu Ser Ile Leu Arg Ala His Glu Ala Gln Asp Ala Gly Tyr 
        275                 280                 285             


Arg Met Tyr Arg Lys Ser Gln Thr Thr Gly Phe Pro Ser Leu Ile Thr 
    290                 295                 300                 


Ile Phe Ser Ala Pro Asn Tyr Leu Asp Val Tyr Asn Asn Lys Ala Ala 
305                 310                 315                 320 


Val Leu Lys Tyr Glu Asn Asn Val Met Asn Ile Arg Gln Phe Asn Cys 
                325                 330                 335     


Ser Pro His Pro Tyr Trp Leu Pro Asn Phe Met Asp Val Phe Thr Trp 
            340                 345                 350         


Ser Leu Pro Phe Val Gly Glu Lys Val Thr Glu Met Leu Val Asn Val 
        355                 360                 365             


Leu Asn Ile Cys Ser Asp Asp Glu Leu Gly Ser Glu Glu Asp Gly Phe 
    370                 375                 380                 


Asp Gly Ala Thr Ala Ala Ala Arg Lys Glu Val Ile Arg Asn Lys Ile 
385                 390                 395                 400 


Arg Ala Ile Gly Lys Met Ala Arg Val Phe Ser Val Leu Arg Glu Glu 
                405                 410                 415     


Ser Glu Ser Val Leu Thr Leu Lys Gly Leu Thr Pro Thr Gly Met Leu 
            420                 425                 430         


Pro Ser Gly Val Leu Ser Gly Gly Lys Gln Thr Leu Gln Ser Ala Thr 
        435                 440                 445             


Val Glu Ala Ile Glu Ala Asp Glu Ala Ile Lys Gly Phe Ser Pro Gln 
    450                 455                 460                 


His Lys Ile Thr Ser Phe Glu Glu Ala Lys Gly Leu Asp Arg Ile Asn 
465                 470                 475                 480 


Glu Arg Met Pro Pro Arg Arg Asp Ala Met Pro Ser Asp Ala Asn Leu 
                485                 490                 495     


Asn Ser Ile Asn Lys Ala Leu Thr Ser Glu Thr Asn Gly Thr Asp Ser 
            500                 505                 510         


Asn Gly Ser Asn Ser Ser Asn Ile Gln 
        515                 520     


<210>  4
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Unphosphorylated amino acid sequence corresponding to SEQ ID NO:1

<400>  4

Pro Gln His Lys Ile Thr Ser Phe Glu Glu Ala 
1               5                   10      


<210>  5
<211>  11
<212>  PRT
<213>  Homo sapiens

<400>  5

Pro Pro His Arg Ile Cys Ser Phe Glu Glu Ala 
1               5                   10      


<210>  6
<211>  11
<212>  PRT
<213>  Homo sapiens

<400>  6

Leu Gln His Lys Ile Arg Ser Phe Glu Glu Ala 
1               5                   10      


<210>  7
<211>  121
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Heavy chain variable region (VH) of phosphospecific S469 
       CNA-alpha antibody

<400>  7

Glu Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Leu Ser Cys Thr Ala Ser Asp Phe Asn Ile Lys Asp Thr 
            20                  25                  30          


Tyr Ile His Trp Leu Lys Gln Arg Pro Glu Gln Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Arg Ile Asp Pro Ala Asn Ser Asn Pro Lys Tyr Asp Pro Asn Phe 
    50                  55                  60                  


Gln Gly Lys Ala Thr Ile Thr Thr Asp Thr Ser Ser Asn Thr Ala Tyr 
65                  70                  75                  80  


Leu Gln Leu Ser Ser Leu Thr Ser Asp Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Thr Arg Arg Asp Tyr Tyr Gly Ser Gly Ser Trp Phe Ala Tyr Trp Gly 
            100                 105                 110         


Gln Gly Thr Leu Val Thr Val Ser Ser 
        115                 120     


<210>  8
<211>  420
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Heavy chain variable region (VH) DNA (including leader sequence 
       DNA)

<400>  8
atgaaatgca gctgggttat cttcttcctg atggcagtgg ttacaggggt caattcagag       60

gttcagctgc agcagtctgg ggcagagctt gtgaggccag gggcctcagt caagttgtcc      120

tgcacagctt ctgacttcaa cattaaagac acctatattc actggttgaa gcagaggcct      180

gaacagggcc tggagtggat tggaagaatt gatcctgcga atagtaatcc taaatatgac      240

ccgaacttcc agggcaaggc cactataaca acagacacat cctccaacac agcctacctg      300

cagctcagca gcctgacatc tgacgacact gccgtctatt actgtactag gagggattac      360

tacggtagtg gttcctggtt tgcttactgg ggccaaggga ctctggtcac tgtctcttct      420


<210>  9
<211>  112
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Light chain variable region (VH) of phosphospecific S469 
       CNA-alpha antibody

<400>  9

Asp Ile Val Met Thr Gln Ala Ala Pro Ser Val Pro Val Thr Pro Gly 
1               5                   10                  15      


Glu Ser Val Ser Ile Ser Cys Arg Ser Ser Lys Ser Leu Leu His Ser 
            20                  25                  30          


Asn Gly Asn Thr Tyr Leu Tyr Trp Phe Leu Gln Arg Pro Gly Gln Ser 
        35                  40                  45              


Pro Gln Leu Leu Ile Tyr Arg Met Ser Asn Leu Ala Ser Gly Val Pro 
    50                  55                  60                  


Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Ala Phe Thr Leu Arg Ile 
65                  70                  75                  80  


Asn Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln His 
                85                  90                  95      


Leu Glu Tyr Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys 
            100                 105                 110         


<210>  10
<211>  396
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Light chain variable region (VH) DNA (including leader sequence 
       DNA)

<400>  10
atgaggtgcc tagctgagtt cctggggctg cttgtgctct ggatccctgg agccattggg       60

gatattgtga tgactcaggc tgcaccctct gtacctgtca ctcctggaga gtcagtatcc      120

atctcctgca ggtctagtaa gagtctcctg catagtaatg gcaacactta cttgtattgg      180

ttcctacaga ggccaggcca gtctcctcaa ctcctgatat atcggatgtc caaccttgcc      240

tcaggagtcc cagacaggtt cagtggcagt gggtcaggaa ctgctttcac actgagaatc      300

aatagagtgg aggctgagga tgtgggtgtt tattactgta tgcaacatct agaatatccg      360

ctcacgttcg gtgctgggac caagctggag ctgaaa                                396


<210>  11
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Heavy chain CDR1 (HC CDR1) of phosphospecific S469 CNA-alpha 
       antibody

<400>  11

Asp Thr Tyr Ile His 
1               5   


<210>  12
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Heavy chain CDR2 (HC CDR2) of phosphospecific S469 CNA-alpha 
       antibody

<400>  12

Arg Ile Asp Pro Ala Asn Ser Asn Pro Lys Tyr Asp Pro Asn Phe Gln 
1               5                   10                  15      


Gly 
    


<210>  13
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Heavy chain CDR3 (HC CDR3) of phosphospecific S469 CNA-alpha 
       antibody

<400>  13

Arg Asp Tyr Tyr Gly Ser Gly Ser Trp Phe Ala Tyr 
1               5                   10          


<210>  14
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Light chain CDR1 (LC CDR1) of phosphospecific S469 CNA-alpha 
       antibody

<400>  14

Arg Ser Ser Lys Ser Leu Leu His Ser Asn Gly Asn Thr Tyr Leu Tyr 
1               5                   10                  15      


<210>  15
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Light chain CDR2 (LC CDR2) of phosphospecific S469 CNA-alpha 
       antibody

<400>  15

Arg Met Ser Asn Leu Ala Ser 
1               5           


<210>  16
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Light chain CDR3 (LC CDR3) of phosphospecific S469 CNA-alpha 
       antibody

<400>  16

Met Gln His Leu Glu Tyr Pro Leu Thr 
1               5                   


<210>  17
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Heavy chain variable region leader sequence

<400>  17

Met Lys Cys Ser Trp Val Ile Phe Phe Leu Met Ala Val Val Thr Gly 
1               5                   10                  15      


Val Asn Ser 
            


<210>  18
<211>  20
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Light chain variable region leader sequence

<400>  18

Met Arg Cys Leu Ala Glu Phe Leu Gly Leu Leu Val Leu Trp Ile Pro 
1               5                   10                  15      


Gly Ala Ile Gly 
            20  


